We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04196257
Recruitment Status : Recruiting
First Posted : December 12, 2019
Last Update Posted : October 31, 2022
Sponsor:
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.

Brief Summary:
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Endometrial Cancer Peritoneal Cancer Solid Tumor Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors
Actual Study Start Date : August 19, 2022
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: BP1001-A monotherapy
Dose escalation of BP1001-A monotherapy
Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.

Experimental: BP1001-A and Paclitaxel
Dose expansion of selected dose of BP1001-A with paclitaxel
Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.




Primary Outcome Measures :
  1. Identify Dose Limiting Toxicity (DLT) of BP1001-A [ Time Frame: 30 days ]
    Identify DLT of BP1001-A using non-hematologic and and hematologic measures per NCI CTCAE criteria

  2. Identify maximum tolerated dose (MTD) of BP1001-A [ Time Frame: 30 days ]
    Identify MTD based on dose limiting toxicities (DLT) of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

  3. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A [ Time Frame: 30 days ]
    Identify and grade TEAE of escalating doses of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

  4. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxel [ Time Frame: 30 days ]
    Identify and grade TEAE of BP1001-A in combination with paclitaxel using non-hematologic and hematologic measures per NCI CTCAE criteria


Secondary Outcome Measures :
  1. Frequency and severity of Adverse Events (AEs) of BP1001-A monotherapy and in combination with paclitaxel [ Time Frame: 30 days ]
    Determine frequency and grade of AEs per NCI CTCAE criteria

  2. Determine objective response rate (ORR) by biopsy [ Time Frame: 180 days ]
    Determine ORR by tumor biopsy using Response Criteria in Solid Tumors (RECIST)

  3. Determine objective response rate (ORR) by imaging [ Time Frame: 180 days ]
    Determine ORR by MRI or CT imaging using Response Criteria in Solid Tumors (RECIST)

  4. Describe duration of overall response (OR) [ Time Frame: 180 days ]
    Describe duration of OR using tumor biopsy per RECIST

  5. Describe duration of objective response (OR) [ Time Frame: 180 days ]
    Describe duration of OR using MRI or CT imaging per RECIST

  6. Describe duration of stable disease by imaging [ Time Frame: 180 days ]
    Describe duration of stable using MRI or CT imaging per RECIST

  7. Describe duration of stable disease by tumor biopsy [ Time Frame: 180 days ]
    Describe duration of stable disease using tumor biopsy per RECIST

  8. Describe progression-free survival (PFS) per RECIST by biopsy [ Time Frame: 360 days ]
    Describe PFS using tumor biopsy per RECIST

  9. Describe progression-free survival (PFS) per RECIST by imaging [ Time Frame: 360 days ]
    Describe PFS using MRI or CT imaging per RECIST

  10. Determine plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (Cmax) [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using maximum plasma drug concentration (Cmax)

  11. Determine plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (Tmax) [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using time of maximal observed concentration (Tmax)

  12. Determine plasma pharmacokinetics (PK)of BP1001-A monotherapy and in combination with paclitaxel (AUC) [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using Area Under the Curve (AUC)

  13. Determine plasma pharmacokinetics of BP1001-A monotherapy and in combination with paclitaxel (CL) [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using clearance rate (CL)

  14. Determine half-life plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (t1/2) [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using mean terminal elimination half life (t1/2)

  15. Frequency and severity of AEs of BP1001-A in combination with paclitaxel [ Time Frame: 30 days ]
    Determine frequency and grade of AEs of BP1001-A in combination with paclitaxel per NCI CTCAE criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All participants, ≥ 18 years of age, with histologic evidence of advanced or recurrent solid tumors, who are not candidates for regimens or protocol treatments known to confer clinical benefit.
  2. ECOG Performance Status Score of 0 or 1.
  3. Participants must be willing to undergo pre-treatment biopsies. Participants who complete 1 cycle of treatment will undergo post-treatment biopsies. Post-treatment biopsies will be offered to participants who do not complete 1 cycle of treatment.
  4. For the dose expansion phase, participants must have recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube or endometrial tumor and must be participants for whom single agent paclitaxel would be considered a reasonable treatment option.
  5. Endometrial cancer patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, squamous cell, transitional cell carcinoma, and mesonephric carcinoma.

    Ovarian tumor patients with the following histologic epithelial cell types are eligible: High-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, squamous carcinoma, transitional cell (Brenner) carcinoma, mixed epithelial-stromal carcinoma, undifferentiated or other epithelial carcinoma.

    Uterine carcinosarcoma and other sarcomas of the uterus are not eligible.

  6. Estimated life expectancy > 3 months in the Investigator's opinion.
  7. All participants must have measurable disease per RECIST criteria v1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be >/= 20 mm when measured by conventional techniques, including plain x-ray, CT, and MRI, or >/= 10 mm when measured by spiral CT. Measurable disease lesions must be amenable to pre- and post-treatment biopsy.
  8. Participants must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
  9. Participants must have adequate:

    1. Bone marrow function: HgB >/= 9 g/dL, WBC >/= 3,000/mcL, ANC >/= 1,500/mcL, PLT >/= 100,000/mcL
    2. Hepatic function: Total bilirubin within normal institutional limits, AST and ALT < 2.5 X institutional ULN
    3. Renal function: Serum creatinine < 1.5 x ULN or eGFR > 60 mL/min according to Cockcroft-Gault formula
    4. Neurologic function: Neuropathy (sensory and motor) </= CTCAE Grade 1
    5. Blood coagulation parameters: PT such that INR is < 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin or low molecular weight heparin) and a PTT < 1.2 times control
  10. Participants previously treated with docetaxel (regardless of response) are eligible for this trial.
  11. Participants in the dose expansion phase who previously received paclitaxel for primary or recurrent disease are eligible if they did not progress on therapy or relapse within 6 months of completing therapy. Participants with persistent disease at the completion of primary therapy with paclitaxel are not eligible.
  12. Participants should be free of active infection requiring antibiotics, with the exception of uncomplicated UTI.
  13. Any hormonal therapy directed at the malignant tumor must be discontinued at least two weeks prior to BP1001-A treatment. Continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy for prostate cancer (e.g., leuprolide, a gonadotropin-releasing hormone [GnRH] agonist), ovarian or breast cancer are not exclusionary.
  14. Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to first dose of BP1001-A (6 weeks for nitrosoureas or mitomycin C).
  15. Female participants of childbearing potential must have a negative urine pregnancy test performed within 24 hours prior to the start of study treatment. Post-menopausal subjects (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  16. Female participants of childbearing potential must agree to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of treatment.
  17. Male participants must agree to use an acceptable method of contraception for the duration of the study.
  18. Participants must be willing and able to provide written informed consent.

Exclusion Criteria:

  1. For the dose expansion phase, participants must not have low grade serous ovarian carcinoma or mucinous ovarian carcinoma.
  2. For the dose expansion phase, participants must wait at least two weeks after receiving any strong inhibitor, inducer, or substrate of both CYP3A4 and CYP2C8 before investigational drug administration.
  3. Participants who had previous bone marrow or hematopoietic stem cell transplant.
  4. Participants may not be receiving any other investigational agents.
  5. Female participants who are pregnant or breast-feeding.
  6. History or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months of registration on this study.
  7. Within the past 6 months, participant has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident, or transient ischemic attack.
  8. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, NYHA class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia, or clinically significant baseline ECG abnormality (e.g., QTcF >470 msec).
  9. Active pleural effusion or pleural or pericardial effusion with symptoms. Pleural or pericardial effusion that has received treatment and resolved according to the Investigator, is acceptable.
  10. Participants who are ineligible to undergo an MRI scan for reasons such as claustrophobia or the presence of implanted devices or metallic foreign bodies that are not MR compatible, such as ferromagnetic implants or pacers or with a known history of allergic reaction to gadolinium contrast agents.
  11. Any condition which, in the Investigator's opinion, makes the subject unsuitable for trial participation.
  12. A prior history of ≥ Grade 3 hypersensitivity to paclitaxel or docetaxel or with products mixed in Cremephor EL or Tween 80®.
  13. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy or procedure, excluding alopecia.
  14. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  15. Participants with HIV infection who have CD4+ T-cell counts < 350 cells/mcL or with clinically active hepatitis B or C infection.
  16. Participants who have a major surgical procedure, open biopsy, dental extractions, or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to registration.
  17. (For dose expansion phase) Subjects ineligible or unable to receive paclitaxel as treatment for their disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04196257


Contacts
Layout table for location contacts
Contact: Brian Forbes 832-742-1365 bforbes@biopathholdings.com
Contact: Michael Hickey 832-742-1361 mhickey@biopathholdings.com

Locations
Layout table for location information
United States, Texas
Mary Crowley Cancer Research Recruiting
Dallas, Texas, United States, 75230
Contact: Joshua Matson    214-545-3933    jomatson@marycrowley.org   
Principal Investigator: Minal Barve, M.D.         
The University of Texas M.D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Shannon Westin, M.D., M.P.H.    713-794-4314      
Principal Investigator: Shannon Westin, MD         
Sponsors and Collaborators
Bio-Path Holdings, Inc.
Layout table for additonal information
Responsible Party: Bio-Path Holdings, Inc.
ClinicalTrials.gov Identifier: NCT04196257    
Other Study ID Numbers: BP1001-A-101-GynOnc
First Posted: December 12, 2019    Key Record Dates
Last Update Posted: October 31, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Carcinoma, Ovarian Epithelial
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Fallopian Tube Diseases
Adnexal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Ovarian Neoplasms
Endocrine Gland Neoplasms
Ovarian Diseases
Endocrine System Diseases
Gonadal Disorders
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action